Publications by authors named "T N Omar"

Percutaneous superficial femoral interventions remain the preferred method of treatment for superficial femoral artery (SFA) disease. Nevertheless, long term restenosis continues to be a major limitation of percutaneous interventions. In this context, the objective of this study is to compare the efficacies of CHA2DS2-VASc, CHA2DS2-VASc-HS, ATRIA, ATRIA-HSV, and HATCH risk scoring systems in predicting long-term (5 years) restenosis due to percutaneous interventions to the superficial femoral artery.

View Article and Find Full Text PDF

Background: Liver disease is the leading cause of non-AIDS-related mortality in people living with HIV (PLWH). Steatotic liver disease (SLD) is increasingly recognised as an important aetiological factor in liver dysfunction in PLWH.

Objectives: This study aimed to determine the post-mortem prevalence and severity of SLD and determine HIV- and non-HIV-related risk factors associated with it.

View Article and Find Full Text PDF

This study used Raman and near-infrared (NIR) spectroscopy to monitor small real-time changes in powder blends and tablets in low-dose pharmaceutical formulations. The research aims to enhance process analytical technology (PAT) in pharmaceutical manufacturing, ensuring high-quality and uniform products with applications to produce drugs with narrow therapeutic indices (NTI). The study utilizes Raman and NIR spatially resolved spectroscopy (SRS) techniques to monitor a moderate cohesive material's active pharmaceutical ingredient (API) concentrations during manufacturing.

View Article and Find Full Text PDF

Background: S. haematobium is a recognized carcinogen and is associated with squamous cell carcinoma of the bladder. Its association with high-risk(HR) human papillomavirus (HPV) persistence, cervical pre-cancer and cervical cancer incidence has not been fully explored.

View Article and Find Full Text PDF

Favipiravir, a high dose antiviral drug effective for oral treatment for COVID-19, with poor water solubility is formulated using a simple, low-cost melt coating and granulation methodology. High-dose (82.5 % w/w API) tablets (600 mg and 800 mg) with desired release profiles are developed while minimizing excipient burden.

View Article and Find Full Text PDF